Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4870-4875

  Tashiro, Masato ^a   Izumikawa, Koichi ^a   Hirano, Katsuji ^a   Ide, Shotaro ^a   Mihara, Tomo ^a   Hosogaya, Naoki ^a,b   Takazono, Takahiro ^a   Morinaga, Yoshitomo ^c   Nakamura, Shigeki ^a   Kurihara, Shintaro ^c   Imamura, Yoshifumi ^a   Miyazaki, Taiga ^a   Nishino, Tomoya ^a   Tsukamoto, Misuzu ^c   Kakeya, Hiroshi ^a   Yamamoto, Yoshihiro ^a   Yanagihara, Katsunori ^c   Yasuoka, Akira ^c   Tashiro, Takayoshi ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CORRELATION ANALYSIS; FUNGUS ISOLATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGAL PROTEINS; HUMANS; ITRACONAZOLE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; PULMONARY ASPERGILLOSIS; TIME FACTORS; TRIAZOLES;

EID: 84865418348     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00514-12     Document Type: Article

References (33)

1. Alanio A, et al. 2011. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J. Antimicrob. Chemother. 66:371-374.
2. Arabatzis M, et al. 2011. Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece. Antimicrob. Agents Chemother. 55:3025-3030. doi:10.1128/AAC.01491-10.
3. Arendrup MC, et al. 2010. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 5:e10080. doi:10.1371/journal.pone.0010080.
4. Balajee SA, et al. 2007. Aspergillus species identification in the clinical setting. Stud. Mycol. 59:39-46. (Pubitemid 351155585)
5. Barone JA, et al. 1998. Enhanced bioavailability of itraconazole in hydroxypropyl- beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob. Agents Chemother. 42:1862-1865. (Pubitemid 28311595)
6. Bellete B, et al. 2010. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med. Mycol. 48:197-200. doi:10.3109/13693780902717018.
7. Bueid A, et al. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65:2116-2118.
8. Camps SMT, et al. 2012. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob. Agents Chemother. 56:10-16. doi: 10.1128/AAC.05088-11.
9. Chen J. 2005. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother. 55:31-37. (Pubitemid 40192611)
10. Chowdhary A, et al. 2012. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J. Antimicrob. Chemother. 67:362-366.
11. Dannaoui E, et al. 2001. Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 47:333-340. (Pubitemid 32229575)
12. de Valk HA, et al. 2005. Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J. Clin. Microbiol. 43:4112-4120.
13. Escribano P, et al. 2012. In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations. Antimicrob. Agents Chemother. 56:174-178. doi:10.1128/AAC.00301-11.
14. Espinel-Ingroff A, et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48:3251-3257.
15. Guinea J, Recio S, Pelaez T, Torres-Narbona M, Bouza E. 2008. Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era. Antimicrob. Agents Chemother. 52:3444-3446. doi:10.1128/AAC.00629-08.
16. Hinrikson HP, Hurst SF, Lott TJ, Warnock DW, Morrison CJ. 2005. Assessment of ribosomal large-subunit D1-D2, internal transcribed spacer 1, and internal transcribed spacer 2 regions as targets for molecular identification of medically important Aspergillus species. J. Clin. Microbiol. 43:2092-2103. (Pubitemid 40656213)
17. Howard SJ, et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
18. Izumikawa K, Takazono T, Kohno S. 2010. Chronic Aspergillus infections of the respiratory tract: diagnosis, management and antifungal resistance. Curr. Opin. Infect. Dis. 23:584-589.
19. Kohno S, Izumikawa K. 2010. Posaconazole for chronic pulmonary aspergillosis: the next strategy against the threat of azole resistant Aspergillus infection. Clin. Infect. Dis. 51:1392-1394.
20. Kohno S, et al. 2010. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J. Infect. 61:410-418. doi:10.1016/j.jinf.2010.08.005.
21. Kume H, et al. 2011. Epidemiology of visceral mycoses in autopsy cases in Japan: comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in annual of pathological autopsy cases in Japan. Med. Mycol. J. 52:117-127.
22. Mortensen KL, et al. 2011. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J. Clin. Microbiol. 49:2243-2251.
23. Mortensen KL, et al. 2010. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob. Agents Chemother. 54:4545-4549. doi:10.1128/AAC.00692-10.
24. Pfaller M, et al. 2011. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J. Clin. Microbiol. 49:586-590.
25. Pfaller MA, et al. 2009. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
26. Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJG. 2010. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob. Agents Chemother. 54:2425-2430. doi:10.1128/AAC.01599-09.
27. Snelders E, et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219. doi:10.1371/journal.pmed.0050219.
28. Tashiro M, et al. 2012. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob. Agents Chemother. 56:584-587. doi:10.1128/AAC.05394-11.
29. Tashiro T, et al. 2011. Diagnostic significance of Aspergillus species isolated from respiratory samples in an adult pneumology ward. Med. Mycol. 49:581-587.
30. Verweij PE, Howard SJ, Melchers WJG, Denning DW. 2009. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
31. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. 2009. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9:789-795.
32. Walsh Thomas J, et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
33. Willems L, van der Geest R, de Beule K. 2001. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J. Clin. Pharm. Ther. 26:159-169. (Pubitemid 32592545)